Segui
Zeda Zhang
Titolo
Citata da
Citata da
Anno
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer
P Mu, Z Zhang, M Benelli, WR Karthaus, E Hoover, CC Chen, ...
Science 355 (6320), 84-88, 2017
8852017
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes
EJ Adams, WR Karthaus, E Hoover, D Liu, A Gruet, Z Zhang, H Cho, ...
Nature 571 (7765), 408-412, 2019
1952019
Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer
Z Zhang, WR Karthaus, YS Lee, VR Gao, C Wu, JW Russo, M Liu, ...
Cancer Cell 38 (2), 279-296. e9, 2020
1682020
Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation
Z Zhang, C Zhou, X Li, SD Barnes, S Deng, E Hoover, CC Chen, YS Lee, ...
Cancer cell 37 (4), 584-598. e11, 2020
1082020
ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis
R Bose, WR Karthaus, J Armenia, W Abida, PJ Iaquinta, Z Zhang, ...
Nature 546 (7660), 671-675, 2017
822017
Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones
D Liang, Y Feng, F Zandkarimi, H Wang, Z Zhang, J Kim, Y Cai, W Gu, ...
Cell 186 (13), 2748-2764. e22, 2023
802023
A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon
D Gao, Y Zhan, W Di, AR Moore, JJ Sher, Y Guan, S Wang, Z Zhang, ...
PLoS One 11 (8), e0161084, 2016
242016
Macrophages promote anti-androgen resistance in prostate cancer bone disease
XF Li, C Selli, HL Zhou, J Cao, S Wu, RY Ma, Y Lu, CB Zhang, B Xun, ...
Journal of Experimental Medicine 220 (4), e20221007, 2023
172023
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
N Mao, Z Zhang, YS Lee, D Choi, AA Rivera, D Li, C Lee, S Haywood, ...
Nature Communications 12 (1), 5053, 2021
162021
A SMAD4‐modulated gene profile predicts disease‐free survival in stage II and III colorectal cancer
BC Szeglin, C Wu, MR Marco, HS Park, Z Zhang, B Zhang, ...
Cancer Reports 5 (1), e1423, 2022
112022
Oncogenic ERG represses PI3K signaling through downregulation of IRS2
N Mao, D Gao, W Hu, S Gadal, H Hieronymus, S Wang, YS Lee, ...
Cancer research 80 (7), 1428-1437, 2020
112020
Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer
E Lee, Z Zhang, CC Chen, D Choi, ACA Rivera, E Linton, Y Ho, J Love, ...
bioRxiv, 2024.03. 18.585532, 2024
2024
Abstract NG06: CHD1-loss confers AR targeted therapy resistance via promoting cancer heterogeneity and lineage plasticity
Z Zhang, C Zhou, X Li, S Barnes, S Deng, E Hoover, CC Chen, YS Lee, ...
Cancer Research 80 (16_Supplement), NG06-NG06, 2020
2020
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–13